financetom
Business
financetom
/
Business
/
Paytm to shut Canada B2C app to focus all resources on India business
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Paytm to shut Canada B2C app to focus all resources on India business
Jan 14, 2022 9:54 AM

Paytm has announced that it will be shutting down its Canada app from March 14. The company has explained that the shutdown will enable it to focus all its resources on India. The B2C app, meant for making bill payments and scheduling future bill payments, was launched on 2017.

Share Market Live

NSE

"In order to focus all our resources on the massive India opportunity, and given the immateriality of the Canada B2C app, we have decided to sunset the Canada B2C app only with effect from March 14, 2022," Paytm said in a filing.

Also read: Paytm Payments Bank receives 'scheduled bank' status from RBI

The company had first launched its Canadian division, called Paytm Labs, at Toronto, Canada. The division was started as a research and development division working on big data, artificial intelligence and machine learning to improve Paytm’s financial products. While Paytm Labs will still exist, it will focus its research on India instead.

"As a part of our Canada operations, we launched a small experiment in the country with a B2C app. Over the last few years, we have built Paytm Labs, our team in Canada to drive innovation for our products and services across the world, whose primary business, amongst others, is research and development analytics of customer data and provision of technical support. We are so proud of this team that continues to innovate and explore more exciting and new opportunities," Paytm said.

Also read: Global market conditions impacted Paytm IPO, says Vijay Shekhar Sharma

Paytm will not be laying off any employees as a result of the shutdown, reported The Economic Times.

The Paytm stock has continued to slide rapidly over the past few weeks. Paytm shares closed at an all-time low of Rs 1,031.4 on January 13, less than half the value of its IPO price of Rs 2,150. The company has seen a precipitous 33.77 percent drop over the past month.

While Macquarie analysts have pegged a target price of Rs 900 for the scrip, other brokerages like Morgan Stanley, JP Morgan and Goldman Sachs, among others, have set up bullish target prices in the range of Rs 1,600-1,900.

Also read: Paytm shares rebound after sliding below Rs 1,000 mark for first time ever

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved